








Anixa Biosciences is a clinical-stage biotechnology company developing first-in-class products for cancer treatment and prevention. Anixa's programs use the body's immune system to take multiple approaches in fighting cancer—vaccines to prevent cancer, and a CAR-T cell therapy to treat cancer.

The Company's vaccines focus on immunizing against "retired" proteins found to be expressed in certain forms of cancer. This mechanism has never before been utilized for cancer vaccine development. Anixa's lead vaccine program targets triple negative breast cancer (TNBC), the most aggressive and lethal form of the disease. Anixa's second preventative vaccine targets ovarian cancer. The breast cancer vaccine is being studied in a Phase 1 clinical trial with Cleveland Clinic, while the ovarian cancer vaccine is in pre-clinical development. Anixa's cancer treatment program, also targeting ovarian cancer, explores an immunotherapy using a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. This therapy is in a Phase 1 clinical trial with Moffitt Cancer Center.

By partnering with world-renowned research institutions on clinical development, Anixa maintains a capital-efficient and low-cost business model that facilitates ongoing identification and examination of emerging technologies in complementary fields for potential development and commercialization.

Key Programs & Development Partnerships

THERAPEUTIC AREA	MECHANISM OF ACTION	INDICATION	GEOGRAPHIC RIGHTS	STAGE	UPCOMING MILESTONES	PARTNERS
Oncology	Vaccine	Breast Cancer	Global	Phase 1	Additional Phase 1a,b,c data releases	 
Oncology	Vaccine	Ovarian Cancer	Global	Pre-clinical	Initiate IND enabling studies	  
Oncology	CAR-T Therapeutic	Ovarian Cancer / Other Solid Tumors	Global	Phase 1	Periodic data releases (enrollment based)	 

Investment Highlights

Robust pipeline in oncology/immunology. Multiple value-creating catalysts for clinical programs over next 12 months: 3 candidates, 2 modalities, 3 indications, 2 clinical trials.

Positive Phase 1 clinical data. Breast cancer vaccine: 75% of women showed immune responses with responses observed at all dose levels. Ovarian cancer immunotherapy: no dose-limiting toxicities observed in 1st cohort.

Strong financial profile. Capital-efficient, low-cost business model with research support from key partners. ~\$5-6M annual cash burn since 2017. Cash and equivalents of \$24M and \$0 debt (10/31/23).

Clean capital structure. 31M common shares outstanding, no preferred shares, and no warrants.

High-value partnerships. Licensing, funding, and collaboration with top-tier, world-renowned research organizations and institutions.

Significant TAM opportunity. ~3.8M breast cancer survivors¹. ~230,000 women living with ovarian cancer¹. All women potentially eligible for vaccines: ~168M in the U.S. alone.

Proven management and board. Decades of success in starting, building, managing, and investing in technology-related companies. Scientific advisory from renowned doctors in oncology research.

Consistent Insider Buying. Consistent stock purchases by CEO and Board insiders.

¹National Cancer Institute.

Global Markets



Triple-Negative Breast Cancer.²

Value: \$11B 2022

Expected value: \$20B

CAGR: 12.1% 2023-2030

²Zion Market Research, Sept. 2023



Ovarian Cancer Drugs.³

Value: \$2.3B 2021

Expected value: \$5.1B

CAGR: 8.4% 2021-2031

³Allied Market Research, Nov. 2023

Science

Imagine if the immune system could be trained to kill cancer cells as they arise before they form into tumors. Perhaps, this could eliminate the onset of cancer. The challenge for scientists has been to identify an agent that allows the immune system to target malignant cells without harming healthy tissue. Cleveland Clinic has identified two such protein agents.


Breast Cancer—Alpha-lactalbumin

- Present in healthy breast tissue during lactation.
- Disappears after a woman stops nursing her child.
- Presents in many types of breast cancer.

Ovarian Cancer—Anti-Mullerian hormone receptor II (AMHR2-ED)

- Expressed in normal ovaries.
- Ceases to express after menopause.
- Expressed in cancerous ovary cells.

By developing vaccines that target alpha-lactalbumin and AMHR2-ED, Anixa believes the immune system can destroy breast cancer cells and ovarian cancer cells as they arise, and ultimately prevent tumors from forming.



Recent News

- February 12, 2024: [Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial](#)
- January 23, 2024: [Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology](#)
- December 6, 2023: [Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine](#)
- October 13, 2023: [Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial](#)

Recent Video

- YouTube Video: [Anixa Biosciences; Diving Into Some Recent Pivotal Data from the Company](#)

2024 Conferences

- March: NeauxCancer 2024 Conference

Leadership Team



AMIT KUMAR, PH.D., Chairman & Chief Executive Officer

Investor, founder, director and CEO of several technology enterprises, both public and private. CombiMatrix Corporation, OAK Investment Partners, Acacia Research Corporation, former American Cancer Society board member.



MICHAEL CATELANI, President, COO & CFO

Seasoned executive with over 30 years of finance and operations management experience. Tacere Therapeutics, Benitec Biopharma, Axon Instruments, Ernst & Young.



PAMELA D. GARZONE, PH.D., Chief Development Officer

Senior pharmaceutical executive with over 25 years of strategic, scientific, clinical and regulatory leadership in drug development. Calibr/Scripps Research Institute, Pfizer, Elan Pharmaceuticals, Genetics Institute, Genentech.

Market Snapshot*

Share Price	52-Wk. Range	Avg. Vol.	Shares O/S	Market Cap
\$4.05 (2/16/24)	\$2.75 - \$6.45	220K	31M	\$128.3M
Analyst coverage: H.C. Wainwright				

Contact

3150 Almaden Expressway, Suite 250
San Jose, CA 95118

Mike Catelani, President, COO & CFO
(408) 708-9808 - mcatelani@anixa.com

*Price and volume quotes from Yahoo! Finance

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences' current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A – Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.